Kaposi Sarcoma Clinical Trial
Official title:
Essai de Phase II Multicentrique évaluant le Pembrolizumab Dans le Traitement de la Maladie de Kaposi Classique ou endémique
Classic and endemic Kaposi's sarcoma (KS) are lymphangio-proliferations associated with human
herpes virus 8 (HHV8), which treatment is poorly codified. Chemotherapies give at best 30-60%
of transient responses. While interferon responses are frequent, this drug is often poorly
tolerated in elderly patients. Therefore new therapies are needed. Classic KS represents an
ideal model for evaluating new drugs since patients do not receive concomitant
immunosuppressive regimens nor antiviral therapies.
Pembrolizumab, an anti-PD1 monoclonal antibody has recently been shown to improve survival in
several solid tumors. In KS few data are available on the role of PD1-PD-L1 axis. A
significant PD-L1 expression on HHV8-associated pleural effusion lymphomas and on KS samples
have been recently reported. Our experience in classical and endemic KS supports the role of
this pathway with expression of PD-L1 by subpopulations of T cells but also NK cells in
peripheral blood cells from these patients and expression of PD-L1 by tumor cells in KS
lesions.
In this study we will evaluate the benefit and safety profile of pembrolizumab in classic and
endemic KS.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04941274 -
Abemaciclib in Patients With HIV-associated and HIV-negative Kaposi Sarcoma
|
Phase 1/Phase 2 | |
| Completed |
NCT03160183 -
Investigating Chemotherapy Treatments, Response and Subsets of HIV-associated Kaposi Sarcoma in Malawi
|
||
| Recruiting |
NCT03993106 -
A Study of sEphB4-HSA in Kaposi Sarcoma
|
Phase 2 | |
| Recruiting |
NCT05081141 -
HHV8 and Solid Organ Transplantation
|
||
| Completed |
NCT00395278 -
Development of Serologic Assays for Human Herpes Virus-8
|
||
| Recruiting |
NCT02408861 -
Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
|
Phase 1 | |
| Completed |
NCT03296553 -
Impact of Valganciclovir on Severe IRIS-Kaposi Sarcoma Mortality: an Open-label, Parallel, Randomized Controlled-trial.
|
Phase 2 | |
| Recruiting |
NCT04305691 -
Trial of Ixazomib for Kaposi Sarcoma
|
Phase 2 | |
| Completed |
NCT03316274 -
Intra-lesional Nivolumab Therapy for Limited Cutaneous Kaposi Sarcoma
|
Early Phase 1 | |
| Recruiting |
NCT05859074 -
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
|
Phase 1 | |
| Terminated |
NCT04893018 -
NT-I7 for Kaposi Sarcoma in Patients With or Without HIV
|
Phase 1 | |
| Recruiting |
NCT06375122 -
Natural History Study of Kaposi Sarcoma
|
||
| Recruiting |
NCT05663502 -
Collecting Blood and Tissue Sample Donations for Research for HIV/AIDS-Related Cancers
|
||
| Recruiting |
NCT05329792 -
L19IL2/L19TNF in Skin Cancer Patients
|
Phase 2 | |
| Not yet recruiting |
NCT05411237 -
Paclitaxel and Pegylated Liposomal Doxorubicin for Treatment of HIV-related Kaposi Sarcoma
|
Phase 3 | |
| Completed |
NCT03050788 -
Smartphone Confocal Microscopy for Diagnosing Kaposi's Sarcoma
|
N/A | |
| Completed |
NCT03404297 -
Compression Therapy for Leg Ulcers and Kaposi Sarcoma in Western Kenya
|
N/A | |
| Terminated |
NCT01412515 -
A Phase II Study With Tumor Molecular Pharmacodynamic (MPD) Evaluation of Oral mTOR-inhibitor Everolimus (RAD001) 10 mg Daily in Patients Suffering From Classic or Endemic Kaposi's Sarcoma
|
Phase 2 | |
| Not yet recruiting |
NCT06004011 -
AYAHIV Role-based Responsibilities for Oncology-focused Workforce (ARROW)
|
N/A | |
| Withdrawn |
NCT02229981 -
Early Phase Evaluation of ABC294640 in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma or Kaposi Sarcoma
|
Phase 1/Phase 2 |